final program.qxd - Parallels Plesk Panel

PP 1.20
Study of the anti-HIV recombinant vaccinia viruses
Babkin I.V., Babkina I.N., Nesterov A.E., Ryazankin I.A., Danilyuk N.K., Seregin S.V.,
Belavin P.A., Bazhan S.I., Shchelkunov S.N.
State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk
region, Russia
The goal of this project is to design anti-HIV vaccines involving recombinant vaccinia
viruses and to research vaccines immunogenicity. Two recombinant vaccinia virusescandidate
anti-HIV vaccines-were produced by homologous recombination between the
earlier constructed integration plasmids and vaccinia virus (strain Lister variant LIVP) at
TK-flanking segments of thymidine kinas gene. The recombinant viruses were created:
VV-TCI, VV-TCI-HBsAg. Earlier the artificial T cellular immunogen TCI containing about 80
CTL epitopes selected from the database on HIV molecular immunology was constructed.
The genetic constructs expressing the artificial TCI protein and TCI protein fused to the
HBsAg were obtained. The immunogenic properties of development recombinant viruses
were studied after a single intracutaneous immunization of BALB/c mice at a dose of
2 × 106 PFU per animal. The recombinant viruses studied induce both cell-mediated and
humoral immunity to HIV proteins. Immunization of mice by VV-TCI resulted in a more
pronounced humoral immune response. The results of CTL study demonstrated that a
statistically significant increase in the activity of cytotoxic T lymphocytes in response to
stimulation occurred on day 7 post immunization of mice and remained until the end of
experiment. The maximal statistically significant activation of spleenocytes from the
animals immunized with VV-TCI and VV-TCI-HbsAg by recombinant HIV proteins
occurred on day 21 post vaccination. The data obtained show that recombinant virus
VV-TCI may be considered as the best candidate vaccine against human
immunodeficiency virus.
“ Focusing FIRST on PEOPLE “ 104 w w w . i s h e i d . c o m